Brief: Revive Therapeutics Files For FDA Orphan Drug Designation For Bucillamine
23/11/2021 14:30
Nov 23 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS FILES FOR FDA ORPHAN DRUG DESIGNATION
FOR
BUCILLAMINE IN THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
DURING LIVER TRANSPLANTATION
Source text for Eikon: ID:nGNX7GKgGx
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure